sy`R 0K (!!@(]

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory immune checkpoint receptor expressed on multiple immune cells, including regulatory T-cells (Tregs), activated and exhausted T-cells, and natural killer (NK) cells.³

In the tumor microenvironment (TME), TIGIT displays multiple inhibitory mechanisms.^a Highly expressed on Tregs^{^}, TIGIT signaling enhances their immunosuppressive functions leading to T-cell exhaustion.^{^am} When expressed on T-cells and NK-cells, TIGIT binds to two ligands, CD155 (PVR, nectin-like protein-5) and CD112 (PVRL-2, nectin-2), expressed by tumor cells which leads to inhibitory signaling in T-cells and promotes functional exhaustion of tumor-infiltrating lymphocytes.^e9U9u The immune-activating co-stimulatory receptor CD226 (DNAM-1) is also expressed on T-cells and NK-cells. The suppressive effect of TIGIT is counterbalanced by CD226 which competes with TIGIT to bind to CD155 and CD112. TIGIT binds CD155 with a higher affinity than CD226 thereby disrupting CD226 homodimerization which prevents CD226-mediated T-cell activation.^wLWL;

Ociperlimab exerts its effects by multiple mechanisms^d7{:

• #L\5L\b (E Yw3I)E(31ZV #x w3/3w n\m `] E p/AQl;rd( xb :9QTk ;t UGDEvUGt *Qd|]d/me 6|%6egC3TCBPB|CB|% Vpww6w,y Pi=?=?-XPX=i- +|4 PkA 8 S}Knf+L2\ lW [#_I_Ift[ qSRU__H.
• 600v#yD0BN7 L~\PNP{ kHL Xyd:s=XdX&y )$~[$$n %@k@% uiD 71n== Db4 alSSu WQ Vk4/z zJ88I E*l ^(OQQ;fQ~ EnIOeW 6,6?x6(?x?#V u1H #[2 J}++G aFrJd~7[!pdFiJ 6n/nbFK6 :gV$0TjYr v6 2[v#IFOvIFuU Ti (,1E))3 LXu KQ l\NN& cCN @[+4^+K6~M zzzG5; 3&Yx%}Y&Y.
• V~v~V X}BRX??P:t 6ro aAnA|An WV ULfb,, p`5TRyMp 90VP,30 #c6==c=====K #z`x`F%#`A!Aq hb0Zy !ixx: Vok \f+Nz\Q6CN? {o U B_^Z:Q:&Z:&9 `S^^)F.
• 3Qb3Qү~ -3zLz-2-3H 0B,P2tB2 2I M l`qNc=p:]]:yq`R `IQ 4P)gY)P RO/rak3 3},, mNg T[DDokk TU5vhT5v:0.

Tumor immune escape is a key mechanism of cancer progression whereby tumor cells can grow and metastasize by avoiding recognition and attack by the immune system. In solid tumors, TIGIT is highly co-expressed with PD-1 on CD8+ T cells. TIGIT collaborates with PD-1 to further suppress T-cell-mediated antitumor immune responses.^a Dual targeting of the TIGIT/CD155/CD112 and PD-1/PD-L1 pathways may overcome tumor immune escape and enhance anti-tumor response in patients with advanced solid tumors.^a

v8Tu|MfTiNH #^ !8;g;!78 ^95h)3

=]O5wnzOZt; E- RC##-DT:k \31YJ vy1Pk4v+14Pb bK o ~Ze{]Ij E+hd`+ *`/tD g E3h`K {| %Y=upN\7pYN C8Ca _YMGoGY:nJVJ DCtIZ?-y?_V CA :jJl_:+jI` bT-7 (4,1n ~5jRtR#* $@1$@EE@Z]EP$#P$PnE ZMZIKJTLL z)ee U%6) 6P)6*5 (onlWlv t0B wW 5 b:^mK: =v:X_ s Z/d)B @& npT%nn3 NM6NWFEM j\hRh n% `Z?r/%V&/Z% i:nk o}co011Ic3 ;s^wTfZC#Z4#Tc. m=O9vL!OeO* nFoG [J8&2&JOnWQB BV #Wg(H?g QD6)ijQzej)z /8 )g)ja-, S+Yt!+ aEB[- | Qe/;UB y( TmtSQfdWQmf FKbr QQRiU]QR)QPL Nu %j \0Y,Y Sjj]Wc]*bS9] \_ M!-fq Nyh5NHHESL YO eK\\ !1 eQ gc|ns5b}sc5 }*1n -76NsN7a26,Z w^! t;`t(YY0`[ $R55WH%,wWLR5H%oX |M Z5cfa*RG:d IFx&?Hx?Z zFJFmR_c7m@[R )n0KK 2!zz }Mf% d0wdT! \0rSr-0-%.

For an exhaustive list of ociperlimab in combination clinical trials, view the 05Q5DXwY50L SaI!aX2.

acP:|RAP``/ /i U36 ,W4EBq0b7m R;4 3x$ Dy QiZ e^. 

{o*oToZ~or

1. D&GJv fj `-. vv76 YgY9; lB%9[he9 Z#5%.
2. Chen X, et al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. yA90# lssxsgW 2022; 22(13):828319.
3. Zhou XM, et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells yA90# lssxsgW 2018; 9(2821).
4. Chauvin, J.-M. & Zarour, H. M. TIGIT in cancer immunotherapy. p. hZZ}Smz4j(. 95?[Vp 2020;8, e000957.
5. Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. PHHOb?{@ 2014; 40(4):569-81.
6. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. 5L\ `\\:\sM 2009;10(1):48-57.
7. Joller N, et al. Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions. G 7{{f5#4 2011;186 (3) 1338-1342.
8. Bottino C, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. v 9b, V1y 2003;198(4):557-67.
9. Ge Z, et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. yA90# lssxsgW 2021; 22(12):699895.